The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of age on outcomes in men receiving treatment for metastatic castration-resistant prostate cancer (mCRPC): Analysis of Medicare fee for service (FFS) claims data.
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Noxopharm; Roche; Seagen
Speakers' Bureau - Exelixis; Prometheus
Research Funding - Bayer; Bristol-Myers Squibb
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; Bristol-Myers Squibb; Dendreon; Exelixis; Janssen; Novartis; Pfizer; Tempus
Research Funding - Bayer (Inst); Pfizer (Inst)
 
Carl A. Olsson
Employment - Astellas Pharma; Dendreon; miR Scientific; Urotronic
Stock and Other Ownership Interests - Egenix; Exelixis (I)
Research Funding - Advantagene (Inst); Dendreon (Inst); Medivation (Inst)
Travel, Accommodations, Expenses - Integrated Medical Professionals
Other Relationship - American Urological Association
 
Kate Fitch
Research Funding - Dendreon (Inst)
 
Scott Flanders
Employment - Dendreon
Stock and Other Ownership Interests - Johnson & Johnson
Travel, Accommodations, Expenses - Dendreon
 
Celestia S. Higano
Honoraria - Astellas Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Carrick Therapeutics; Clovis Oncology; Clovis Oncology; Ferring; Ferring; Hinova Pharmaceuticals; Hinova Pharmaceuticals; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); eFFECTOR Therapeutics (Inst); Emergent BioSolutions (Inst); Ferring (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Carrick Therapeutics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer